- Home
- NRC vs EVMN Comparison
NRC vs EVMN Comparison
Compare NRC & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRC | EVMN |
|---|---|---|
| Founded | 1981 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.0M | 474.7M |
| IPO Year | 1997 | 2025 |
Fundamental Metrics
Financial Performance| Metric | NRC | EVMN |
|---|---|---|
| Price | $21.87 | $9.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $43.88 |
| AVG Volume (30 Days) | 88.8K | ★ 589.8K |
| Earning Date | 04-28-2026 | 06-11-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | ★ 4707.69 | 75.23 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $119,686,000.00 | $13,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.81 | ★ 85.71 |
| 52 Week Low | $11.01 | $9.20 |
| 52 Week High | $23.68 | $33.20 |
Technical Indicators
Market Signals| Indicator | NRC | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 53.34 | 32.30 |
| Support Level | $21.20 | N/A |
| Resistance Level | $21.74 | $13.35 |
| Average True Range (ATR) | 0.85 | 0.66 |
| MACD | -0.02 | -0.18 |
| Stochastic Oscillator | 73.31 | 10.24 |
Price Performance
Historical ComparisonAbout NRC National Research Corporation (Delaware)
NRC Health operates as a humanized healthcare and support organization. Its platform includes Listen, Understand, and Improve. The group provides solutions for Patient, Consumer, Employee, and Market experiences. The group's commitment to Human Understanding helps healthcare systems get to know the patients, families, consumers, employees, and communities it on a human level.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.